Myocardial ischaemia in patients with impaired left ventricular function undergoing coronary artery bypass

T Möllhoff1, C Schmidt, H Van Aken

  • 1Universitätsklinikum Münster, Klinik and Poliklinik für Anästhesiologie und operative Intensivmedizin, Germany.

Insights

Milrinone infusion significantly reduced myocardial ischemia and cell damage after coronary artery bypass grafting compared to nifedipine. This finding is crucial for improving patient outcomes in high-risk cardiac surgery.

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Pharmacology

Background:

  • Myocardial ischemia and infarction are significant risks following coronary artery bypass grafting (CABG).
  • Potential causes include incomplete revascularization, anesthetic management, and arterial graft vasospasm.
  • Nifedipine and milrinone infusions are considered for preventing internal mammary artery spasm.

Purpose of the Study:

  • To compare the incidence of myocardial ischemia after continuous infusion of nifedipine versus milrinone.
  • To evaluate the efficacy of these agents in patients with compromised left ventricular function undergoing elective CABG.

Main Methods:

  • A double-blinded randomized clinical study involving 30 adult patients with ejection fraction < 0.4.
  • Patients received either nifedipine (0.2 µg/kg/min) or milrinone (0.375 µg/kg/min) infusion.
  • Myocardial ischemia detected by Holter ECG; cell damage assessed by serial CK-MB and troponin-I levels.

Main Results:

  • A significantly lower incidence of ST elevation/depression occurred in the milrinone group (33.3%) compared to the nifedipine group (86.6%) (P < 0.05).
  • Both groups showed increases in CK-MB and troponin-I.
  • Postoperative CK-MB (P = 0.003) and troponin-I (P = 0.001) were significantly higher in the nifedipine group.

Conclusions:

  • Perioperative milrinone infusion significantly reduces myocardial ischemia after CABG compared to nifedipine.
  • Milrinone also leads to less myocardial cell damage in this patient population.
  • These findings suggest milrinone as a potentially superior agent for preventing perioperative ischemia in high-risk CABG patients.
Abstract

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...